742 related articles for article (PubMed ID: 34962662)
1. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
[TBL] [Abstract][Full Text] [Related]
3. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
Natale P; Tunnicliffe DJ; Toyama T; Palmer SC; Saglimbene VM; Ruospo M; Gargano L; Stallone G; Gesualdo L; Strippoli GF
Cochrane Database Syst Rev; 2024 May; 5(5):CD015588. PubMed ID: 38770818
[TBL] [Abstract][Full Text] [Related]
6. Metformin monotherapy for adults with type 2 diabetes mellitus.
Gnesin F; Thuesen ACB; Kähler LKA; Madsbad S; Hemmingsen B
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD012906. PubMed ID: 32501595
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
8. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
9. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
11. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.
Chen Y; Lv X; Lin S; Arshad M; Dai M
Front Endocrinol (Lausanne); 2022; 13():895458. PubMed ID: 35692410
[TBL] [Abstract][Full Text] [Related]
12. Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach.
Brønden A; Christensen MB; Glintborg D; Snorgaard O; Kofoed-Enevoldsen A; Madsen GK; Toft K; Kristensen JK; Højlund K; Hansen TK; Søndergaard E; Hansen KB
Diabet Med; 2023 Aug; 40(8):e15157. PubMed ID: 37249579
[TBL] [Abstract][Full Text] [Related]
13. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q; Nong K; Vandvik PO; Guyatt GH; Schnell O; Rydén L; Marx N; Brosius FC; Mustafa RA; Agarwal A; Zou X; Mao Y; Asadollahifar A; Chowdhury SR; Zhai C; Gupta S; Gao Y; Lima JP; Numata K; Qiao Z; Fan Q; Yang Q; Jin Y; Ge L; Yang Q; Zhu H; Yang F; Chen Z; Lu X; He S; Chen X; Lyu X; An X; Chen Y; Hao Q; Standl E; Siemieniuk R; Agoritsas T; Tian H; Li S
BMJ; 2023 Apr; 381():e074068. PubMed ID: 37024129
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
[TBL] [Abstract][Full Text] [Related]
15. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
[TBL] [Abstract][Full Text] [Related]
16. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
17. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
19. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
[TBL] [Abstract][Full Text] [Related]
20. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]